Christopher J Record,Mariola Skorupinska,Matilde Laura,Alexander M Rossor,Davide Pareyson,Chiara Pisciotta,Shawna M E Feely,Thomas E Lloyd,Rita Horvath,Reza Sadjadi,David N Herrmann,Jun Li,David Walk,Sabrina W Yum,Richard A Lewis,John Day,Joshua Burns,Richard S Finkel,Mario A Saporta,Sindhu Ramchandren,Michael D Weiss,Gyula Acsadi,Vera Fridman,Francesco Muntoni,Roy Poh,James M Polke,Stephan Zuchner,Michael E Shy,Steven S Scherer,Mary M Reilly,Lisa Abreu,Kimberly A Anderson,Silvia Baratta,Debbie Berry,Julian Blake,Eleonora Cavalca,Kayla Cornett,Andrea Cortese,Gabrielle Donlevy,Amanda Dragon,Magdalena Dudziec,Katy Eichinger Tim Estilow,Valerie Ferment,Natalie Grant,Tiffany Grider,Emily Hyslop,Tara Jones,Nicole Kressin,Wendy Leon,Stefania Magri,Brett McCray,Manoj Menezes,Evelin Milev,Lindsey Parrott,Pooja Patel,Cláudia Brito Pires,Valeria Prada,Gita Ramdharry,Paola Saveri,Giulia Schirinzi,Rosemary Shy,Carly Siskind,Janet Sowden,Sydney Stork,Charlotte J Sumner,Franco Taroni,Simone Thomas,Jennifer Twachtman-Bassett,Nidia Villalpando,Dragan Vujovic,Julie Wells,Elizabeth Wood,Riccardo Zuccarino,for the Inherited Neuropathies Consortium - Rare Disease Clinical Research Network

Abstract:Charcot-Marie-Tooth disease (CMT) due to GJB1 variants (CMTX1) is the second most common form of CMT. It is an X-linked disorder characterised by progressive sensory and motor neuropathy with males affected more severely than females. Many reported GJB1 variants remain classified as variants of uncertain significance (VUS). In this large, international, multicentre study we prospectively collected demographic, clinical and genetic data on patients with CMT associated with GJB1 variants. Pathogenicity for each variant was defined using adapted American College of Medical Genetics criteria. Baseline and longitudinal analyses were conducted to study genotype-phenotype correlations, to calculate longitudinal change using the CMT Examination Score (CMTES), to compare males versus females, and pathogenic/likely pathogenic (P/LP) variants versus VUS. We present 387 patients from 295 families harbouring 154 variants in GJB1 . Of these, 319 patients (82.4%) were deemed to have P/LP variants, 65 had VUS (16.8%) and 3 benign variants (0.8%; excluded from analysis); an increased proportion of patients with P/LP variants compared with using ClinVar's classification (74.6%). Male patients (166/319, 52.0%, P/LP only) were more severely affected at baseline. Baseline measures in patients with P/LP variants and VUS showed no significant differences, and regression analysis suggested the disease groups were near identical at baseline. Genotype-phenotype analysis suggested c.-17G>A produces the most severe phenotype of the five most common variants, and missense variants in the intracellular domain are less severe than other domains. Progression of disease was seen with increasing CMTES over time up to 8 years follow-up. Standard response mean (SRM), a measure of outcome responsiveness, peaked at 3 years with moderate responsiveness (change in CMTES (ΔCMTES) = 1.3 ± 2.6, p = 0.00016, SRM = 0.50). Males and females progressed similarly up to 8 years, but baseline regression analysis suggested that over a longer period, females progress more slowly. Progression was most pronounced for mild phenotypes (CMTES = 0-7; 3-year ΔCMTES = 2.3 ± 2.5, p = 0.001, SRM = 0.90). Enhanced variant interpretation has yielded an increased proportion of GJB1 variants classified as P/LP and will aid future variant interpretation in this gene. Baseline and longitudinal analysis of this large cohort of CMTX1 patients describes the natural history of the disease including the rate of progression; CMTES showed moderate responsiveness for the whole group at 3 years and higher responsiveness for the mild group at 3, 4 and 5 years. These results have implications for patient selection for upcoming clinical trials.

Phenotype-driven reanalysis reveals five novel pathogenic variants in 40 exome-negative families with Charcot–Marie–Tooth Disease

[A Genotyping Study of 13 Cases of Early-Onset Charcot-Marie-Tooth Disease].

Genetic Spectrum of MCM3AP and Its Relationship with Phenotype of Charcot‐Marie‐Tooth Disease

Author Response for "genetic Spectrum and Clinical Profiles in a Southeast Chinese Cohort of Charcot‐Marie‐Tooth Disease"

New Clinical Characteristics and Novel Pathogenic Variants of Patients with Hereditary Leukodystrophies

Identification of A Novel SBF2 Frameshift Mutation in Charcot–Marie–Tooth Disease Type 4B2 Using Whole-exome Sequencing

Case Report: Exome Sequencing Achieved a Definite Diagnosis in a Chinese Family with Muscle Atrophy.

Clinical,pathological and Genetic Studies in a Chinese Charcot-Marie-Tooth Disease Type 2 Family

Improving molecular diagnosis of Chinese patients with Charcot-Marie-Tooth by targeted next-generation sequencing and functional analysis.

One PMP22/MPZ and Three MFN2/GDAP1 Concomitant Variants Occurred in a Cohort of 189 Chinese Charcot-Marie-Tooth Families

Screening for SH3TC2, PMP2, and BSCL2 Variants in a Cohort of Chinese Patients with Charcot-Marie-Tooth

Genotype and phenotype distribution of 435 patients with Charcot–Marie–Tooth disease from central south China

Case Report: Charcot-marie-tooth disease caused by a de novo MORC2 gene mutation - novel insights into pathogenicity and treatment

Whole genome sequencing increases the diagnostic rate in Charcot-Marie-Tooth disease

Genetic analysis and natural history of Charcot-Marie-Tooth disease CMTX1 due to GJB1 variants

Clinical and Genetic Diversity of PMP22 Mutations in a Large Cohort of Chinese Patients with Charcot-Marie-Tooth Disease.

IGHMBP2 -Related Clinical and Genetic Features in a Cohort of Chinese Charcot–Marie–Tooth Disease Type 2 Patients

Clinical and genetic spectra in a series of Chinese patients with Charcot–Marie–Tooth disease

Exome Sequencing Reveals a Novel MFN2 Missense Mutation in a Chinese Family with Charcot-Marie-Tooth Type 2A

Clinical and Mutational Spectrum of Paediatric Charcot-Marie-Tooth Disease in a Large Cohort of Chinese Patients.

Targeted next-generation sequencing reveals further genetic heterogeneity in axonal Charcot–Marie–Tooth neuropathy and a mutation in HSPB1